Association of single‐point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes

Abstract

AbstractAimsTo investigate the association of single‐point insulin sensitivity estimator (SPISE) index with future cardiovascular outcomes in patients with type 2 diabetes.Materials and MethodsSPISE index (= 600 × high‐density lipoprotein cholesterol [mg/dL]0.185/triglycerides [mg/dL]0.2 × body mass index [kg/m2]1.338) was calculated in 10 190 participants. Cox proportional hazard regression models were applied to evaluate the association between SPISE index and future cardiovascular outcomes. Restricted cubic spline analyses and two‐piecewise linear regression models were employed to explore the nonlinear association and to determine the threshold value. Subgroup and interaction analyses were conducted to test the robustness of the results.ResultsAfter fully adjusting for well‐established metabolic confounders, higher SPISE index was significantly associated with lower risk of future cardiovascular outcomes in patients with type 2 diabetes (major adverse cardiovascular event [MACE]): hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.90–0.98, p = 0.0026; overall mortality: HR 0.90, 95% CI 0.86–0.93, p < 0.0001; cardiovascular disease [CVD] mortality: HR 0.85, 95% CI 0.79–0.92, p < 0.0001; congestive heart failure (CHF): HR 0.72, 95% CI 0.67–0.78, p < 0.0001; major coronary events: HR 0.91, 95% CI 0.87–0.95, p < 0.0001. There was a nonlinear association between SPISE index and future cardiovascular outcomes (the threshold value was 5.68 for MACE, 5.71 for overall mortality, 4.64 for CVD mortality, 4.48 for CHF, and 6.09 for major coronary events, respectively).ConclusionsHigher SPISE index was independently associated with lower risk of future cardiovascular outcomes in type 2 diabetes patients after full adjustment for well‐established metabolic confounders.